NOVOCART 3D Treatment Following Microfracture Failure

Running, not enrolling · Phase 3

Conditions studied: Articular Cartilage Defect

In brief

This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.

Key facts

Study ID

NCT03219307

Run by

Aesculap Biologics, LLC

People needed

30

Starts

2018-11-30

Expected to finish

2029-01-01

Last updated by the study team

2025-03-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• participated in study AAG-G-H-1220
• identified as a microfracture failure patient
• voluntary consent to participate in the study

You may not qualify if…

• other cartilage repair procedures performed on target knee
• other conditions that would interfere with healing or evaluating outcomes
• lesions requiring implants larger than 9cm2
• non-compliance with requirements in study AAG-G-H-1220

Where it is running

• Rush University Medical Center — Chicago, Illinois, United States
• Ohio State University Wexner Medical Center — Columbus, Ohio, United States
• Alpine Orthopaedics — North Logan, Utah, United States
• University of Alberta — Edmonton, Alberta, Canada
• Dalhousie University — Halifax, Nova Scotia, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.